321 ARSENAL STREET, SUITE 101, WATERTOWN, MA
Restructuring Plan Approved; 20% Workforce Reduction at Disc Medicine
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Investor Presentation
Submits NDA 220707 for Bitopertin Oral Tablets
Reports Third Quarter 2025 Financial Results and Provides Business Update
Material Contracts, Other Events
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities